

In the Claims

1. (Currently Amended) A coating for an implantable medical device, the coating comprising a first region having a polymer and a drug incorporated therein and a second region disposed over the first region,

wherein the second region comprises a polymer and a substance material having [[the]] a melting temperature within the range between about 32 °C and 40 °C for modifying the rate of release of the drug, the polymer in the second region having in a dry state a glass transition temperature within a range of between about 35°C and about 50°C,

wherein the polymer in the second region in the dry state contains less than about 1 mass % of water, and

wherein when the body temperature of a patient in which the device is implanted rises to a temperature above the patient's normal body temperature, the morphology of coating changes so as to change the release rate of the drug in the coating.

2. (Original) The coating of Claim 1, wherein the implantable medical device is a stent.

3. (Original) The coating of Claim 1, wherein the drug is an anti-inflammatory drug.

4. (Currently amended) The coating of Claim 1, wherein the polymer comprises an acrylic polymer[[s]], a non-acrylic polymer[[s]], or blends thereof.

5. (Canceled)

6. (Currently amended) The coating of Claim 4, wherein the non-acrylic polymer[[s are]] is selected from a group consisting of, poly(2-cyclohexylethylethylene), atactic poly(iso-propylethylene), poly(1,1,2-trimethylethylene), poly(4,4 dimethylpentylethylene), poly(2,2,2-trifluoroethoxytrifluoroethylene), poly(4-methoxybenzoylethylene), poly(3,4-

dimethoxybenzoylethylene), poly(vinyl fluoride), poly(cyclopentanoyloxyethylene), 60% syndiotactic poly(formyloxyethylene), poly[4-(*sec*-butoxymethyl) styrene], poly(4-butoxystyrene), and blends thereof.

7. (Cancelled).

8. (Currently amended) The coating of Claim 1, wherein the polymer in the second region has the melting temperature above about 50 °C.

9. (Currently Amended) A coating topcoat for an implantable medical device, comprising a first phase comprising a first polymer, a drug incorporated therein, and a second phase comprising a substance material immiscible with the polymer, the material having [[the]] a melting temperature within the range between about 32 °C and 40 °C,

wherein when the body temperature of a patient in which the device is implanted rises to a temperature above the patient's normal body temperature, the morphology of the coating topcoat changes so as to change the release rate of [[the]] a drug in [[the]] a coating under the topcoat.

10. (Currently Amended) The coating topcoat of Claim 9, wherein the implantable medical device is a stent.

11. (Currently Amended) The coating topcoat of Claim 9, wherein the polymer material has a glass transition melting temperature of the polymer in a dry state is about 37 °C, wherein the polymer in the dry state contains less than about 1 mass % of water.

12. (Currently Amended) The coating topcoat of Claim 9, wherein the polymer comprises an acrylic polymer[[s]], a non-acrylic polymer[[s]], or blends thereof.

13. (Cancelled)

14. (Cancelled)

15. (Currently Amended) The ~~coating topcoat~~ of Claim 12, wherein the non-acrylic polymer[[s are]] is selected from a group consisting of, poly(2-cyclohexylethylethylene), atactic poly(*iso*-propylethylene), poly(1,1,2-trimethylethylene), poly(4,4 dimethylpentylethylene), poly(2,2,2-trifluoroethoxytrifluoroethylene), poly(4-methoxybenzoylethylene), poly(3,4-dimethoxybenzoylethylene), poly(vinyl fluoride), poly(cyclopentanoyloxyethylene), 60% syndiotactic poly(formyloxyethylene), poly[4-(*sec*-butoxymethyl) styrene], poly(4-butoxystyrene), and blends thereof.

16. (Currently Amended) The ~~coating topcoat~~ of Claim 9, wherein the drug is an anti-inflammatory drug.

17-24. (Canceled)